Tegsedi is a medication that has been approved by the FDA for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR). This rare and progressive disease is caused by the buildup of abnormal protein deposits in various tissues and organs, leading to a range of debilitating symptoms.
Tegsedi works by targeting the production of the abnormal protein, helping to slow down the progression of the disease and improve quality of life for patients. It is administered through subcutaneous injections and is typically taken once a week.
As with any medication, there are potential side effects to be aware of when taking Tegsedi. These can include injection site reactions, low platelet counts, and kidney problems. It is important to discuss any concerns or potential side effects with your healthcare provider before starting treatment.
It is also important to follow the dosing instructions provided by your healthcare provider and to attend regular check-ups to monitor your progress while taking Tegsedi. Your healthcare provider may also recommend additional therapies or lifestyle changes to help manage your symptoms and improve your overall health.
If you have been diagnosed with hATTR and are considering treatment with Tegsedi, it is important to have an open and honest discussion with your healthcare provider about the potential benefits and risks of this medication. Together, you can create a treatment plan that is tailored to your individual needs and goals.
EN 
ES 
FR 
PT 
ZH